Labo EuromedisFRA:61R +0.42%61 Days Payable is 79.98 as of Dec. 2025, which is 13% below its 10-year median of 92.13. GuruFocus rates FRA:61R with a GF Score™ of 61/100 and a GF Value™ of €4.37. The stock has 6 warning signs investors should review. Among 115 Medical Distribution companies, Labo Euromedis ranks better than 60.87% on this metric.
The historical rank and industry rank for Labo Euromedis's Days Payable or its related term are showing as below:
FRA:61R'
s Days Payable Range Over the Past 10 Years
Min: 46.85 Med: 92.13 Max: 107.28
Current: 95.34
During the past 13 years, Labo Euromedis's highest Days Payable was 107.28. The lowest was 46.85. And the median was 92.13.
FRA:61R's Days Payable is ranked better than 60.87% of 115
companies
in the Medical Distribution industry
Industry Median: 79.11
vs FRA:61R: 95.34
Labo Euromedis's Days Payable
increased
from Dec. 2024 (74.29) to Dec. 2025 (79.98).
It may suggest that Labo Euromedisdelayed paying its suppliers.
Labo Euromedis Days Payable Related Terms
Labo Euromedis Days Payable Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Labo Euromedis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Days Payable distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Labo Euromedis's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labo Euromedis (FRA:61R) has a Days Payable of 79.98 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Labo Euromedis and its competitors. This is 13% below median its historical median of 92.13. Over the past decade, Labo Euromedis' Days Payable has ranged from 46.85 to 107.28. According to the industry distribution chart, Labo Euromedis ranks #45 out of 115 companies in the Medical Distribution industry, placing it in the top 39.1%.
Is Labo Euromedis' Days Payable too high?
Labo Euromedis' current Days Payable of 79.98 is 13% below median its 10-year median of 92.13. Over the past 10 years, this metric has ranged from a low of 46.85 to a high of 107.28. The Medical Distribution industry median Days Payable is 79.11. Labo Euromedis' value of 79.98 is 1.1% above this industry median. Based on the distribution chart, Labo Euromedis ranks #45 out of 115 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Labo Euromedis has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Days Payable compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #45 out of 115 companies for Days Payable. This puts Labo Euromedis in the upper half of its industry. The industry median Days Payable is 79.11. Labo Euromedis' value of 79.98 is 1.1% above this benchmark. Historically, Labo Euromedis' own Days Payable has ranged from 46.85 to 107.28 over the past decade. While the company's 10-year median is 92.13 vs. the industry median of 79.11, Labo Euromedis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.11, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labo Euromedis's current Days Payable of 79.98 is 1.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Labo Euromedis and its competitors. For the Medical Distribution industry, the median Days Payable is 79.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current Days Payable is 79.98, which is 13% below median its own 10-year median of 92.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Labo Euromedis (FRA:61R) has a current Days Payable of 79.98. The stock's GF Value™ is €4.37, compared to a current price of €4.76 — trading 8.9% above its estimated fair value. The current Days Payable is 79.98, which is 13% below median its 10-year median of 92.13 and 1.1% above the Medical Distribution industry median of 79.11. Labo Euromedis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current Days Payable is 79.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (FRA:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.76 is trading 8.9% above its estimated GF Value™ of €4.37.
Key valuation signals for FRA:61R:
Days Payable: 79.98 (13% below median its 10-year median of 92.13)
GF Value™: €4.37 vs. price of €4.76 (8.9% above fair value)
Industry Position: 1.1% above the Medical Distribution median (#45 of 115)
No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
61GF Score
Get the complete analysis for FRA:61R
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61R has been successfully added to your 
